Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a general health status rated as reasonably functional (scored 0 to 2 on a standard medical scale)
- People who have been newly diagnosed with a specific type of head and neck cancer (squamous cell carcinoma of the upper airways or digestive tract), confirmed by tissue testing, and who have not yet received any treatment for this cancer
- People whose cancer is at a certain stage — specifically stage III (with at least one nearby lymph node involved), stage IVa, or stage IVb — but has not spread to distant parts of the body
- People whose cancer is located in the mouth, voice box (larynx), throat (oropharynx or hypopharynx), or the sinus behind the cheekbone (maxillary sinus)
- People for whom a specialist medical team has agreed that curative radiotherapy — with or without chemotherapy (Cisplatin or Cetuximab) — is the appropriate treatment plan
- People who are willing and able to follow all study procedures as outlined in the protocol
- People who have read, understood, and signed the consent form on the day they join the study
- People who are covered by the social security system (in France)
Who may not be able to join:
- People who are under 18 years of age
- People whose cancer is located in the nasopharynx (cavum), ethmoidal sinus, salivary glands, or skin
- People who have already received treatment for a head and neck cancer of this type
- People who have received immunotherapy treatment
- People who have had another type of cancer (outside the head and neck area) within the past 5 years
- People whose general health status is rated as poor (scored above 2 on the standard medical scale)
- People who have a medical reason that prevents them from safely receiving radiotherapy, with or without the associated chemotherapy drugs
- People who are already enrolled in another clinical treatment trial
- People whose cancer has spread to distant parts of the body (stage IVc, metastatic disease)
- People who are pregnant, possibly pregnant, or currently breastfeeding
- People who are under legal guardianship, protective supervision, or who have had their personal freedoms restricted
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: MARTZ NM Nicolas, MD., Institut de Cancérologie de Lorraine
Phone: 03 83 59 83 07
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the value of measuring the quantity of circulating tumor DNA (tcDNA) at 1 month post-treatment as a predictive factor for progression-free survival at 24 months.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.